Secondary Amides of (<i>R</i>)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase
作者:Thomas D. Aicher、Robert C. Anderson、Jiaping Gao、Suraj S. Shetty、Gary M. Coppola、James L. Stanton、Douglas C. Knorr、Donald M. Sperbeck、Leonard J. Brand、Christine C. Vinluan、Emma L. Kaplan、Carol J. Dragland、Hollis C. Tomaselli、Amin Islam、Robert J. Lozito、Xilin Liu、Wieslawa M. Maniara、William S. Fillers、Dominick DelGrande、R. Eric Walter、William R. Mann
DOI:10.1021/jm990358+
日期:2000.1.1
6-tetrahydropyridine)thiourea, SDZ048-619 (1), is a modest inhibitor (IC(50) = 180 microM) of pyruvate dehydrogenase kinase (PDHK). In an optimization of the N-methylcarbothioamide moiety of 1, it was discovered that amides with a small acyl group, in particular appropriately substituted amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, are inhibitors of PDHK. Utilizing this acyl moiety, herein is
N'-甲基-N-(4-叔丁基-1,2,5,6-四氢吡啶)硫脲SDZ048-619(1)是丙酮酸脱氢酶激酶的适度抑制剂(IC(50)= 180 microM) (PDHK)。在最优化1的N-甲基碳硫酰胺部分时,发现具有小的酰基的酰胺,特别是(R)-3,3,3-三氟-2-羟基-2-甲基-2-丙酸的适当取代的酰胺,是PDHK的抑制剂。本文报道了利用该酰基部分的原理,其导致一系列酰化哌嗪衍生物的优化。哌嗪在2和5位上的甲基取代(具有S和R绝对立体化学)显着提高了前导化合物的效价(> 1,000倍)。当哌嗪的4位被电子贫乏的苯甲酰基部分取代时,该系列化合物的口服生物利用度良好且最佳(通过AUC测定)。(+)-1-N- [2,5-(S,R)-二甲基-4-N-(4-氰基苯甲酰基)哌嗪]-(R)-3,3,3-三氟-2-羟基-2 -甲基丙酰胺(14e)抑制PDHK在主要酶促测定中的IC(50)为16 +/-